FIELD: pharmaceutical chemistry.
SUBSTANCE: group of inventions includes triazine derivatives given in the claims, a medicinal product, a pharmaceutical composition, a method of inhibition and a method of treatment based on them, as well as their use.
EFFECT: triazine derivatives having SHP2 inhibitory activity and used for treatment of hyperproliferative disease associated with SHP2 activity.
17 cl, 4 tbl, 44 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOUNDS WITH SPIRO AND AROMATIC RINGS AND APPLICATION THEREOF | 2019 |
|
RU2781100C1 |
| GEMINALLY SUBSTITUTED CYANOETHYLPYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS | 2014 |
|
RU2664533C2 |
| BICYCLIC COMPOUND AND USE THEREOF FOR SUV39H2 INHIBITION | 2016 |
|
RU2729187C1 |
| BICYCLIC NITROGEN-CONTAINING COMPOUNDS AS AGONISTS OF M1 MUSCARINIC RECEPTORS | 2019 |
|
RU2811601C1 |
| SPIRO CONDENSED PYRROLIDINE DERIVATIVES AS INHIBITORS OF DEUBIQUITINATING ENZYMES (DUB) | 2017 |
|
RU2730552C2 |
| PHENOXYMETHYL DERIVATIVES | 2016 |
|
RU2746481C1 |
| GLP-1 RECEPTOR AGONISTS AND USE THEREOF | 2017 |
|
RU2740135C1 |
| MODULATORS OF ATP-BINDING TRANSPORTERS | 2010 |
|
RU2552353C2 |
| BICYCLIC NITROGEN-CONTAINING COMPOUNDS AS MUSCARINIC M1 RECEPTOR AGONISTS | 2015 |
|
RU2685230C2 |
| SUBSTITUTED PYRROLES ACTIVE AS KINASES INHIBITORS | 2013 |
|
RU2666538C2 |
